Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients

Cheng, Xin; Yu, Guojun; Hu, Jiangping; Xu, Xuefeng; Luo, Fang; Shen, Ping; Zhang, Guosheng; Yang, Ning

doi:10.3892/etm.2016.3307

Cited by 4 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SD can serve as a cheap source including chlorophylls, vitamins, and metal complexes of porphyrins [ 16 ]. SD extract (shengxuening tablet) has been used as an efficient oral iron supplement to IDA [ 36 – 38 ]. SD extract ameliorates various allergy symptoms by regulating Th1/Th2 immune response [ 39 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

Differential Metabolomics and Network Pharmacology Analysis of Silkworm Biotransformation between Mulberry Leaves and Silkworm Droppings

Chen

Dai

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Silkworm droppings are the product of mulberry leaves digested by silkworm intestines, which are an important medicinal resource in traditional Chinese medicine (TCM). The contents of total fat, fat acids, crude protein, amino acids, and secondary metabolites of obtained mulberry leaves and silkworm droppings were analyzed by HPLC, GC-MS, and UHPLC-Q-TOF MS. The target genes and enriched pathways related to significantly changed compositions between mulberry leaves and silkworm droppings were analyzed by network pharmacology. High unsaturated C18 : 3 fatty acids were transformed to low unsaturated C18 : 1 from mulberry leaves to silkworm droppings. Only lysine and 17 mini-peptides had significantly higher content in silkworm droppings than in mulberry leaves. There were 36 common target genes or the different compounds between mulberry leaves and silkworm droppings. The main pathways of mulberry leaf were enriched in antivirus and anticancer properties, while the pathways of silkworm droppings were enriched in hormone regulation and signal transduction.

show abstract

Section: Discussionmentioning

confidence: 99%

Differential Metabolomics and Network Pharmacology Analysis of Silkworm Biotransformation between Mulberry Leaves and Silkworm Droppings

Chen

Dai

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…SXN combined with recombinant human erythropoietin significantly increased the HGB, hematocrit, SF, and transferrin saturation levels in patients with renal anemia [ 9 ]. Similar efficacy was observed in patients with anemia of maintenance hemodialysis [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

“…Shengxuening (SXN) tablet, extracted from the excrement of silkworm (Bombyx mori L.) [ 8 ], has effects of replenishing qi and nourishing blood and has been used to treat anemia [ 9 – 12 ]. Silkworm excrement is nontoxic and has been shown to treat diabetes, fever, arthritis, and so forth [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of SXN in the Treatment of Iron Deficiency Anemia: A Phase IV Clinical Trial

Ding

Xu²,

Jin

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Shengxuening (SXN) tablet is extracted from the excrement of the silkworm and has effects on hematopoiesis. The main components of SXN are chlorophyll derivatives and sodium iron chlorophyllin (SIC). The present study aims to investigate the efficiency and safety of SXN on iron deficiency anemia. This phase IV, multicenter, open-label, randomized clinical trial was conducted in 31 hospitals in China from June 2001 to April 2002. Adults and children were randomly divided into low-dose (L-SXN), medium-dose (M-SXN), and high-dose (H-SXN) groups, respectively. The course of treatment was 1 month. Peripheral hemogram levels and iron status were examined before and after treatment. Adults in all three dose groups demonstrated a significant increase in hemoglobin (HGB) concentration. Children who received SXN treatment in medium and high doses also demonstrated increased HGB concentration. Reticulocyte counts increased at the end of treatment in the M-SXN and H-SXN adult groups and in the M-SXN child group. For both children and adults, SXN in the three dose groups was found to significantly elevate red blood cell level, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. The total effective rate in the SXN-treated group reached 84.8%. The incidence of adverse events was 4.07%. The most common side effects were nausea (2.83%), diarrhea (0.74%), and rash (0.25%). SXN was proved to be efficient and safe for adults and children with iron deficiency anemia.

show abstract

“…SXN exerts remarkable effects against iron deficiency anemia, chronic aplastic anemia, and renal anemia [18–20] . This study aimed to investigate the effects of SXN on hematopoiesis in myelosuppressed mouse model and explore the underlying mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Shengxuening Extracted from Silkworm Excrement Mitigates Myelosuppression via SCF‐Mediated JAK2/STAT3 Signaling

Ding

Tan

Xu³

et al. 2021

Chemistry & Biodiversity

View full text Add to dashboard Cite

Shengxuening (SXN) is a Chinese patent medicine with main ingredients (including chlorophyll derivatives and sodium iron chlorophyllin) extracted from silkworm excrement. SXN exhibited efficacy in clinical trials of renal anemia and iron deficiency anemia; however, the specific mechanisms remain unclear. This study found that SXN increased the number of peripheral blood cells and improved the bone marrow morphology in myelosuppressed mouse model, reversed the reduction in body weight and spleen indices, and increased the serum levels of erythropoietin and granulocyte‐macrophage colony‐stimulating factor. Quantitative real‐time PCR array and Western blot analysis showed the enhanced expression of stem cell factor (SCF), JAK2, and STAT3 in the liver. These results suggested that SXN promoted the recovery of hemopoietic function in myelosuppressed models by increasing the secretion of hematopoietic factors and activating the JAK2/STAT3 pathway. Therefore, this medicine may be applied as therapeutic pharmaceutical drug to mitigate myelosuppression.

show abstract

Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients

Cited by 4 publications

References 20 publications

Differential Metabolomics and Network Pharmacology Analysis of Silkworm Biotransformation between Mulberry Leaves and Silkworm Droppings

Differential Metabolomics and Network Pharmacology Analysis of Silkworm Biotransformation between Mulberry Leaves and Silkworm Droppings

Efficacy of SXN in the Treatment of Iron Deficiency Anemia: A Phase IV Clinical Trial

Shengxuening Extracted from Silkworm Excrement Mitigates Myelosuppression via SCF‐Mediated JAK2/STAT3 Signaling

Contact Info

Product

Resources

About